SELLAS Life Sciences (NASDAQ: SLS) director gets 50,000 RSUs award

Rhea-AI Filing Summary

SELLAS Life Sciences Group director Katherine Bach Kalin reported receiving 50,000 shares of common stock as a stock-based award. The Form 4 shows the transaction occurred on January 7, 2026 and was coded as an acquisition at a price of $0.00 per share, reflecting a grant rather than an open-market purchase.

According to the disclosure, the grant represents 50,000 restricted stock units that will vest in full on December 1, 2026, provided she continues to serve on the company’s board of directors through that date. After this award, she beneficially owns 154,400 shares of SELLAS common stock, held directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kalin Katherine Bach

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	50,000	$0.00	--

Holdings After Transaction: Common Stock — 154,400 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kalin Katherine Bach

(Last) (First) (Middle)

C/O SELLAS LIFE SCIENCES GROUP, INC., 7

TIMES SQUARE, SUITE 2503

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SELLAS Life Sciences Group, Inc. [ SLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/07/2026		A		50,000(1)	A	$0.00	154,400	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

	/s/ Daniel Bagliebter, Power of Attorney for: Katherine Bach Kalin	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did SELLAS (SLS) report for Katherine Bach Kalin?

The company reported that director Katherine Bach Kalin received an award of 50,000 shares of common stock on January 7, 2026 as disclosed on Form 4.

Was the SELLAS (SLS) insider transaction a purchase or a grant?

The filing codes the transaction as an acquisition at $0.00 per share, indicating a stock-based grant rather than an open-market purchase.

What type of equity award did the SELLAS (SLS) director receive?

The footnote explains that the director received 50,000 restricted stock units, each representing a right to receive one share of SELLAS common stock.

When do the 50,000 restricted stock units for the SELLAS (SLS) director vest?

The restricted stock units vest in full on December 1, 2026, subject to the director’s continued service on the board through that date.

How many SELLAS (SLS) shares does the director own after this transaction?

Following the reported grant, the Form 4 states the director beneficially owns 154,400 shares of SELLAS common stock, held directly.

What is the relationship of the reporting person to SELLAS (SLS)?

The reporting person, Katherine Bach Kalin, is identified in the filing as a director of SELLAS Life Sciences Group, Inc.